<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309477</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-PRGNS-002</org_study_id>
    <nct_id>NCT01309477</nct_id>
  </id_info>
  <brief_title>The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a pilot study to explore the efficacy and safety of Tacrolimus Sustained-release
      Capsules (ADVAGRAF) on 6-month induction therapy of Refractory Nephrotic Syndrome (RNS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate (complete or partial remission) at 6 months</measure>
    <time_frame>6 months after therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>every 3 months up to 6 months</time_frame>
    <description>infections, transient increases in serum creatinine, gastrointestinal complaints, liver function disorder and glucose intolerance , etc</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>ADVAGRAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in the study will take the Tacrolimus Sustained-release Capsules (ADVAGRAF) orally at the basis of low dose prednisone treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus Sustained-release Capsules (ADVAGRAF)</intervention_name>
    <description>Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .</description>
    <arm_group_label>ADVAGRAF</arm_group_label>
    <other_name>ADVAGRAF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of either sex, 14-60 years of age

          -  Diagnosis of Nephrotic syndrome with hypoalbuminemia (&lt; 3.0g/dl) and heavy proteinuria
             (&gt; 3.5g/24hr) and exclude secondary Nephrotic syndrome

          -  Refractory Nephrotic Syndrome

               1. Steroid resistant: failure to respond (either complete or partial remission)
                  after a course of 8 weeks of 1.0 mg/kg/d prednisone or equal dose of steroid
                  therapy

               2. Steroid dependent: recurrence of nephrotic proteinuria during tapering of
                  prednisone at a dose &gt; 10 mg/day or within the first 2 weeks after withdrawal of
                  prednisone

               3. Frequently recurrence: initial remission with steroid induction therapy, but
                  relapsed 2 or more in 6 months or 3 or more within 12 months

               4. Failure to respond (either complete or partial remission) even after CTX, MMF or
                  CsA therapy combined with steroid

          -  eGFR â‰¥ 60 ml/min/1.73 m2

          -  Provision of written informed consent by subject or guardian

        Exclusion Criteria:

          -  Systemic disease

          -  eGFR &lt; 60ml/min/1.73m2

          -  Diagnosed DM

          -  Malignant tumors (except fully cured basal cell carcinoma)

          -  Familial nephritic syndrome

          -  History of significant gastrointestinal disorders (e.g. severe chronic diarrhea or
             active peptic ulcer disease) within 3 month prior to enter this study

          -  Any Active systemic infection or history of serious infection within one month of
             entry or known infection with HIV, hepatitis B, or hepatitis C

          -  Known hypersensitivity or contraindication to tacrolimus, corticosteroids

          -  Participation in another clinic trial and/or receipt of investigational drugs within 4
             weeks prior to screening

          -  Pregnancy, nursing or use of a non-reliable method of contraception

          -  Inability or unwillingness to provide written informed consent

          -  Usage of immunosuppression therapy (MMF, CTX, CysA, MTX ect) for more than 1 week
             within 1 month prior to first randomization or intravenous MP Pulse treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Xueqing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>March 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2011</study_first_posted>
  <last_update_submitted>November 1, 2011</last_update_submitted>
  <last_update_submitted_qc>November 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Xueqing Yu</name_title>
    <organization>Sun Yat-sen University</organization>
  </responsible_party>
  <keyword>Refractory Nephrotic Syndrome</keyword>
  <keyword>Tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

